Ethological resolution of behavioural topography and D1-like versus D2-like agonist responses in congenic D5 dopamine receptor mutants: Identification of D5:D2-like interactions

Synapse

Volumn 55, Issue 4, 2005, Pages 201-211

  O'Sullivan, Gerard J ^a   Kinsella, Anthony ^b   Sibley, David R ^c   Tighe, Orna ^a   Croke, David T ^a   Waddington, John L ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

D5 knockout mice; Dopamine receptor subtypes; Ethogram; Grooming behaviour; Seizures

Indexed keywords

1 AMINOMETHYL 5,6 DIHYDROXY 3 PHENYLISOCHROMAN; 3 ALLYL 6 CHLORO 7,8 DIHYDROXY 1 (3 METHYLPHENYL) 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; ADENYLATE CYCLASE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 5 RECEPTOR; N (3 HYDROXYPHENETHYL) N (PHENETHYL)PROPYLAMINE; PHOSPHATIDYLINOSITIDE; PHOSPHOLIPASE C; SKF 83822; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONGENIC STRAIN; CONTROLLED STUDY; ENZYME ACTIVATION; ETHOLOGY; EXPLORATORY BEHAVIOR; FEMALE; GROOMING; HABITUATION; HYDROLYSIS; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REARING; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SEIZURE; STEREOTYPY;

ADENYLATE CYCLASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROOMING; HABITUATION, PSYCHOPHYSIOLOGIC; HYDROLYSIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PHENOTYPE; PHOSPHATIDYLINOSITOLS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D5;

EID: 13844264401     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20107     Document Type: Article

References (49)

1. Andringa G, Drukarch B, Leysen JE, Cools AE, Stoof JC. 1999. The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors. Eur J Pharmacol 364:33-41.
2. Arnt J, Hyttel J, Sanchez C. 1992. Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur J Pharmacol 213:259-267.
3. Banbury Conference. 1997. Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice. Neuron 19:755-759.
4. Baufreton J, Garret M, Rivera A, de la Galle A, Gonon F, Dufy B, Bioulac B, Taupignon A. 2003. D5 (not D1) dopamine receptors potentiate burst-firing in neurons of the subthalamic nucleus by modulating an L-type calcium conductance. J Neurosci 23:816-825.
5. Berridge KC, Aldridge JW. 2000. Super-stereotypy II: enhancement of a complex movement sequence by intraventricular dopamine D1 agonists. Synapse 37:205-215.
6. Centonze D, Grande C, Saulle E, Martin AB, Gubellini P, Pavon N, Pisani A, Bernardi G, Moratalla R, Calabresi P. 2003. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 23:8506-8512.
7. Ciliax BJ, Nash N, Heilman C, Sunahara R, Hartney A, Tiberi M, Rye DB, Caron MG, Niznik HB, Levey AI. 2000. Dopamine D(5) receptor immunolocalization in rat and monkey brain. Synapse 37:125-145.
8. Clifford JJ, Tighe O, Croke DT, Sibley DR, Drago J, Waddington JL. 1998. Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the DlA dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology 37:1595-1602.
9. Clifford JJ, Tighe O, Croke DT, Kinsella A, Sibley DR, Drago J, Waddington JL. 1999. Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience 93:1483-1489.
10. 2 dopamine receptor. Neuropharmacology 39:382-390.
11. Clifford JJ, Kinsella A, Tighe O, Rubinstein M, Grandy DK, Low MJ, Croke DT, Waddington JL. 2001. Comparative, topographically-based evaluation of behavioural phenotype and specification of D(1)-like:D(2) interactions in a line of incipient congenic mice with D(2) dopamine receptor "knockout." Neuropsychopharmacology 25:527-536.
12. Clifford JJ, Drago J, Natoli AL, Wong JY, Kinsella A, Waddington JL, Vaddadi KS. 2002. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 109:81-88.
13. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, Hitzemann RJ, Maxson SC, Miner LL, Silva AJ, Wehner JM, Wynshaw-Boris A, Paylor R. 1997. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132:107-124.
14. Cromwell HC, Berridge KC. 1996. Implementation of action sequences by a neostriatal site: a lesion mapping study of grooming syntax. J Neurosci 16:3444-3458.
15. DeNinno MP, Schoenleber R, MacKenzie R, Britton DR, Asin KE, Briggs C, Trugman JM, Ackerman M, Artman L, Bednarz L, Bhatt R, Curzon P, Gomez E, Kang CH, Stittsworth J, Kebabian JW. 1991. A68930: a potent agonist selective for the dopamine D1 receptor. Eur J Pharmacol 199:209-219.
16. Elliot EE, Sibley DR, Katz JL. 2003. Locomotor and discriminative- stimulus effects of cocaine in dopamine D5 receptor knockout mice. Psychopharmacology 169:161-168.
17. Heyer J, Xiao Q, Bugaj-Gaweda B, Ramboz S, Unterbeck A. 2002. Conditional inactivation of the dopamine receptor 5 gene: flanking the Drd5 gene with loxP sites. Genesis 32:102-104.
18. Hollon TR, Bek MJ, Lachowicz JE, Ariano MA, Mezey E, Ramachandran R, Wersinger SR, Soares-da-Silva P, Liu ZF, Grinberg A, Drago J, Young WS 3rd, Westphal H, Jose PA, Sibley DR. 2002. Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. J Neurosci 22:10801-10810.
19. Holmes A, Hollon TR, Gleason TC, Liu Z, Dreiling J, Sibley DR, Crawley JN. 2001. Behavioral characterization of dopamine D5 receptor null mutant mice. Behav Neurosci 115:1129-1144.
20. Homanics GE, Quinlan JJ, Firestone LL. 1999. Pharmacologic and behavioral responses of inbred C57BL/6J and strain 129/SvJ mouse lines. Pharmacol Biochem Behav 63:21-26.
21. Jin LQ, Goswami S, Cai G, Zhen X, Friedman E. 2003. SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J Neurochem 85:378-386.
22. Kebabian JW, Calne DB. 1979. Multiple receptors for dopamine. Nature 277:93-96.
23. Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M. 1992. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229:203-209.
24. Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S, Zhang G, Bunzow JR, Fang Y, Gerhardt GA, Grandy DK, Low MJ. 1998. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18:3470-3479.
25. Khan ZU, Gutierrez A, Martin R, Penafiel A, Rivera A, de la Calle A. 2000. Dopamine D5 receptors of rat and human brain. Neuroscience 100:689-699.
26. McNamara FN, Clifford JJ, Tighe O, Kinsella A, Drago J, Fuchs S, Croke DT, Waddington JL. 2002. Phenotypic, ethologically based resolution of spontaneous and D(2)-like vs D(1)-like agonist-induced behavioural topography in mice with congenic D(3) dopamine receptor "knockout." Synapse 46:19-31.
27. McNamara FN, Clifford JJ, Tighe O, Kinsella A, Drago J, Croke DT, Waddington JL. 2003. Congenic D1A dopamine receptor mutants: ethologically based resolution of behavioural topography indicates genetic background as a determinant of knockout phenotype. Neuropsychopharmacology 28:86-99.
28. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
29. Molloy AG, Waddington JL. 1984. Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390. Psychopharmacology 82:409-410.
30. Nally RE, McNamara FN, Clifford JJ, Kinsella A, Tighe O, Croke DT, Fienberg AA, Greengard P, Waddington JL. 2003. Topographical assessment of ethological and dopamine receptor agonist-induced behavioral phenotype in mutants with congenic DARPP-32 "knockout." Neuropsychopharmacology 28:2055-2063.
31. Nally RE, Kinsella A, Tigne O, Croke DT, Fienberg AA, Greengard P, Waddington JL. 2004. Ethologically based resolution of D2-like dopamine receptor agonist- vs antagonist-induced behavioural topography in kDa "knockout" mutants congenic on the C57BL/6 genetic background. J Pharmacol Exp Ther 310:1281-1287.
32. Niznik HB, Sugamori KS, Clifford JJ, Waddington JL. 2002. D1-like dopamine receptors: molecular biology and pharmacology. In: Di Chiara G, editor. Handbook of experimental pharmacology: dopamine in the CNS. Heidelberg: Springer, p 121-158.
33. O'Sullivan GJ, Roth BL, Kinsella A, Waddington JL. 2004. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography. Eur J Pharmacol 486:273-280.
34. Panchalingam S, Undie AS. 2001. SKF83959 exhibits biochemical agonism by stimulating [(35)S]GTP gamma S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 40:826-837.
35. Rivera A, Alberti I, Martin AB, Narvaez JA, de la Galle A, Moratalla R. 2002. Molecular phenotype of rat striatal neurons expressing the dopamine D5 receptor subtype. Eur J Neurosci 16:2049-2058.
36. Rosengarten H, Friedhoff AJ. 1998. A phosphoinositide-linked dopamine D1 receptor mediates repetitive jaw movements in rats. Biol Psychiatry 44:1178-1184.
37. Sibley DR. 1999. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol 39:313-341.
38. Sibley DR, Monsma FJ Jr, Shen Y. 1993. Molecular neurobiology of dopaminergic receptors. Int Rev Neurobiol 35:391-415.
39. Starr MS. 1996. The role of dopamine in epilepsy. Synapse 22:159-194.
40. Starr MS, Starr BS. 1993. Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. J Neural Transm Park Dis Dement Sect 6:27-34.
41. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH, Niznik HB. 1991. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350:614-619.
42. Svenningsson P, Le Moine C. 2002. Dopamine D1/5 receptor stimulation induces c-fos expression in the subthalamic nucleus: possible involvement of local D5 receptors. Eur J Neurosci 15:133-142.
43. Tiberi M, Jarvie KR, Silvia C, Falardeau P, Gingrich JA, Godinot N, Bertrand L, Yang-Feng TL, Fremeau RT Jr, Caron MG. 1991. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc Natl Acad Sci USA 88:7491-7495.
44. Tomiyama K, McNamara FN, Clifford JJ, Kinsella A, Drago J, Fuchs S, Grandy DK, Low MJ, Rubinstein M, Tighe O, Croke DT, Koshikawa N, Waddington JL. 2004. Comparative phenotypic resolution of spontaneous, D2-like and Dl-like agonist-induced orofacial movement topographies in congenic mutants with dopamine D2 vs. D3 receptor "knockout." Synapse 51:71-81.
45. Undie AS, Friedman E. 1994. Inhibition of dopamine agonist-induced phosphoinositide hydrolysis by concomitant stimulation of cyclic AMP formation in brain slices. J Neurochem 63:222-230.
46. Undie AS, Weinstock J, Sarau HM, Friedman E. 1994. Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J Neurochem 62:2045-2048.
47. Waddington JL, Daly SA, McCauley PG, O'Boyle KM. 1994. Levels of functional interaction between D1-like and D2-like dopamine receptor systems. In: Niznik HB, editor. Dopamine receptors and transporters: pharmacology, structure and function. New York: Marcel Dekker. p 511-537.
48. Waddington JL, Daly SA, Downes RP, Deveney AM, McCauley PG, O'Boyle KM. 1995. Behavioural pharmacology of "D-1-like" dopamine receptors: further subtyping, new pharmacological probes and interactions with "D-2-like" receptors. Prog Neuropsychopharmacol Biol Psychiatry 19:811-831.
49. Waddington JL, Clifford JJ, McNamara FN, Tomiyama K, Koshikawa N, Croke DT. 2001. The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ("knockout"). Prog Neuropsychopharmacol Biol Psychiatry 25:925-964.